CD44-positive prostate cancer cells were also reported to be resistant to docetaxel after a few months of treatment due to the elevation of AKT-dependent drug transporter ABCB1 and expression of class III β-tubulin [71]. The gene discussed is CD44; the disease is prostate carcinoma.